Investors
A proven track record of value creation
Our diversified business model allows us to respond to opportunities, while delivering for our stakeholders.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
- Hikma announces CEO change and Board appointment Press Release, Corporate 15 December 2025 Hikma announces CEO change and Board appointment
- Inspiring women of Hikma - Meet Cristina Cagnazzi, Finance Director, Hikma Italy Story, Leadership 15 December 2025 Inspiring women of Hikma - Meet Cristina Cagnazzi, Finance Director, Hikma Italy
- European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada Insight, Corporate 08 December 2025 European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada
- Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Press Release, Product 08 December 2025 Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
